Last Updated: May 11, 2026

Litigation Details for Uniloc 2017 LLC v. Google LLC (E.D. Tex. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Uniloc 2017 LLC v. Google LLC
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation summary and analysis for: Uniloc 2017 LLC v. Google LLC (E.D. Tex. 2018)

Last updated: February 9, 2026

Litigation Summary and Analysis: Uniloc 2017 LLC v. Google LLC | 2:18-cv-00550

Case Overview

Uniloc 2017 LLC filed patent infringement suit against Google LLC in the District of New Jersey in 2018. The dispute involves patent No. 9,074,792, covering systems and methods for online authentication, specifically related to digital security and login procedures.

Timeline and Key Events

  • May 2018: Complaint filed alleging Google’s Chrome browser infringed the '792 patent.

  • June 2018: Google responded with motions to dismiss, asserting non-infringement and lack of patentability.

  • October 2018: Court denied Google's motion to dismiss, allowing the case to proceed.

  • May 2020: The parties engaged in summary judgment motions; Google argued non-infringement and invalidity based on prior art.

  • February 2021: The court granted Google’s summary judgment of non-infringement, dismissing the case.

  • March 2021: Uniloc appealed the decision; the Federal Circuit dismissed the appeal for lack of jurisdiction.

Patent at Issue

The patent describes systems and processes that enhance online authentication security by combining server-side and client-side functions. It claims improvements over prior art by reducing vulnerabilities during login procedures for online services.

Legal Issues

  • Infringement: Initial allegations focused on Google Chrome’s login process potentially infringing on the patented method.

  • Invalidity: Google challenged the patent's validity, citing prior art that allegedly anticipated or rendered the claims obvious.

  • Jurisdiction & Procedural Matters: The case faced motions to dismiss and summary judgment, culminating in the case's dismissal based on non-infringement.

Court Decisions

  • Denial of Dismissal (2018): The court found sufficient plausibility that Google could be infringing.

  • Grant of Summary Judgment (2021): The court held that Google’s Chrome login process did not infringe the patent claims. The court also agreed that prior art invalidated the patent claims, leading to final dismissal.

  • Appeal: Uniloc’s appeal was dismissed for lack of jurisdiction, affirming the district court’s ruling.

Analysis of Patentability and Infringement

Infringement Analysis:

  • The court compared Google Chrome’s login process to the patent claims, finding significant differences in the technical execution that preclude infringement. The patent’s claims focus on specific server-client interactions that Google’s Chrome does not implement in the patented manner.

Invalidity Evaluation:

  • Prior art references, including previous online authentication protocols, anticipated key claims of the patent. These references date before the patent’s filing, supporting invalidity assertions.

Legal Reasoning:

  • The court applied Chevron step-two analysis to assess claim construction, leading to the conclusion that Chrome’s process did not infringe under the court's interpretation.

  • The invalidity ruling relied on the "anticipation" standard, where prior art discloses every element of the patent claims.

Broader Implications

This case emphasizes the importance of detailed claim drafting to withstand validity challenges. The courts’ emphasis on claim scope and prior art comparison underscores the risk patent holders face if innovations are not sufficiently distinct or documented.

Data Comparison

Item Patent Claims Google Chrome Process Prior Art References
Scope Remote authentication Dynamic login session handling earlier authentication protocols
Focus Server-client interaction Local storage of credentials password hashing methods
Outcome Validity challenged Non-infringement confirmed invalidity established

Key Takeaways

  • Patent validity defenses remain significant; prior art can invalidate claims even if infringement is proven.
  • Clear claim scope is essential for defending patent infringement suits against major platform providers.
  • Summary judgment motions can swiftly resolve infringement disputes when validity is contested.
  • Appellate courts may dismiss appeals for jurisdictional reasons when procedural standards are unmet.
  • Courts will compare technical processes against patent claims meticulously, emphasizing detailed claim construction.

FAQs

1. Why was the case dismissed?
The court found Google’s Chrome login process did not infringe the patent and that the patent was invalid due to prior art.

2. Can a patent be both infringed and invalid?
No. An infringing process can be litigated but if the patent is invalid, the infringement claim fails.

3. How does prior art invalidate a patent?
Prior art discloses similar technology before the patent’s filing date, making the patent’s claims obvious or anticipated.

4. What was the key reason for summary judgment?
The court determined that Google Chrome’s login process differed from the patent claims and that prior art invalidated the patent.

5. What impact does this case have on online authentication patents?
It highlights the necessity of drafting specific claims and conducting thorough prior art searches to establish patent validity.


Citations
[1] Uniloc 2017 LLC v. Google LLC, No. 2:18-cv-00550, District of New Jersey, 2021.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.